In March 2017, the WHO reclassified progestogen-only injectable contraceptives including DMPA (also known as Depo) and NET-EN as MEC 2, the classification for methods for which the benefits outweigh the theoretical risks, emphasizing that women had a right to know about all of the risks and benefits associated with a method. This step reflected ongoing concern about the possibility that injectable progestogen-contraceptives increase women’s risk of acquiring HIV. There are mixed data from observational studies, primarily focused on DMPA, with far less known about NET-EN or about the subcutaneous formulation of DMPA, branded as Sayana Press. An ongoing randomized controlled trial known as ECHO, scheduled to release data in 2019, is evaluating whether DMPA injections, the copper IUD and the contraceptive implant impact women’s HIV risk. This session will provide updates on the array of moving pieces, including the research, programmatic and advocacy components, and their implications.

• Presentations
• Map